[糖尿病、冠状动脉疾病与心脏病（2023年更新）]
[Diabetes mellitus, coronary artery disease and heart disease (Update 2023)].
作者信息
Clodi Martin, Saely Christoph H, Hoppichler Friedrich, Resl Michael, Steinwender Clemens, Stingl Harald, Wascher Thomas C, Winhofer Yvonne, Sourij Harald
机构信息
Abteilung für Innere Medizin, Konventhospital der Barmherzigen Brüder Linz, Linz, Österreich.
Klinisches Forschungsinstitut für Kardiometabolische Forschung, Johannes Kepler Universität Linz, Altenberger Straße 69, 4040, Linz, Österreich.
出版信息
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):201-206. doi: 10.1007/s00508-023-02183-7. Epub 2023 Apr 20.
Abstract
Diabetes mellitus, cardiovascular disease and heart failure are interacting dynamically. Patients being diagnosed with cardiovascular disease should be screened for diabetes mellitus. Enhanced cardiovascular risk stratification based on biomarkers, symptoms and classical risk factors should be performed in patients with preexisting diabetes mellitus. In patients with previously diagnosed arterosclerotic cardiovascular disease an agent proven to reduce major adverse cardiovascular events or cardiovascular mortality is recommended.
摘要
糖尿病、心血管疾病和心力衰竭之间存在动态相互作用。被诊断患有心血管疾病的患者应进行糖尿病筛查。对于已患有糖尿病的患者，应基于生物标志物、症状和经典危险因素进行强化心血管风险分层。对于先前已诊断患有动脉粥样硬化性心血管疾病的患者，建议使用已证实可降低主要不良心血管事件或心血管死亡率的药物。
相似文献
1
[Diabetes mellitus, coronary artery disease and heart disease (Update 2023)].[糖尿病、冠状动脉疾病与心脏病（2023年更新）]
Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):201-206. doi: 10.1007/s00508-023-02183-7. Epub 2023 Apr 20.
2
[Diabetes mellitus, coronary artery disease und heart disease (Update 2019)].[糖尿病、冠状动脉疾病与心脏病（2019年更新）]
Wien Klin Wochenschr. 2019 May;131(Suppl 1):169-173. doi: 10.1007/s00508-019-1488-3.
3
[Diabetes mellitus, coronary artery disease and heart disease].
Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S212-5. doi: 10.1007/s00508-016-0988-7.
4
High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus.高敏肌钙蛋白 I 和 B 型利钠肽生物标志物用于预测伴或不伴糖尿病的冠状动脉疾病患者的心血管事件。
Cardiovasc Diabetol. 2019 Dec 17;18(1):171. doi: 10.1186/s12933-019-0974-2.
5
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.罗格列酮与冠状动脉旁路移植术血管重建糖尿病患者的结局研究 2 型糖尿病亚组分析（BARI 2D 试验）。
Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.
6
Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial.荷兰初级保健中 2 型糖尿病或慢性阻塞性肺疾病成人主动策略早期检测心血管疾病与常规护理的诊断收益（RED-CVD）：一项多中心、实用、集群随机、对照试验。
Lancet Public Health. 2024 Feb;9(2):e88-e99. doi: 10.1016/S2468-2667(23)00269-4. Epub 2023 Dec 19.
7
WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study.白细胞计数可预测糖尿病合并冠心病患者的心力衰竭：一项回顾性队列研究。
ESC Heart Fail. 2021 Oct;8(5):3748-3759. doi: 10.1002/ehf2.13513. Epub 2021 Jul 15.
8
Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.20 年的心血管并发症和 2 型糖尿病患者的危险因素：一项全国性瑞典队列研究。
Circulation. 2023 Jun 20;147(25):1872-1886. doi: 10.1161/CIRCULATIONAHA.122.063374. Epub 2023 May 8.
9
Coronary Artery Calcium Score directed risk stratification of patients with Type-2 diabetes mellitus.冠状动脉钙评分指导 2 型糖尿病患者的危险分层。
Diabetes Metab Syndr. 2022 Jun;16(6):102503. doi: 10.1016/j.dsx.2022.102503. Epub 2022 May 19.
10
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.在患有冠状动脉疾病和 2 型糖尿病的患者中，使用连续的利钠肽测量可改善即将发生的心血管死亡和心力衰竭住院的风险估计。
J Am Heart Assoc. 2022 Apr 19;11(8):e021327. doi: 10.1161/JAHA.121.021327. Epub 2022 Apr 6.
引用本文的文献
1
Coronary imaging characteristics and risk factors in patients with type 2 diabetes mellitus with coronary heart disease complication.2型糖尿病合并冠心病并发症患者的冠状动脉成像特征及危险因素
World J Diabetes. 2025 Apr 15;16(4):99151. doi: 10.4239/wjd.v16.i4.99151.
本文引用的文献
1
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.达格列净治疗射血分数轻度降低或保留的心力衰竭。
N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27.
2
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.2型糖尿病中射血分数保留的心力衰竭（HFpEF）：从病理生理学到治疗方法
J Mol Cell Biol. 2022 Sep 12;14(5). doi: 10.1093/jmcb/mjac028.
3
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
4
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
5
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
6
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.达格列净与2型糖尿病患者的心血管结局。回复
N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837.
7
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.2 型糖尿病与心力衰竭：欧洲心脏病学会心力衰竭协会立场声明。
Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8.
8
Atherosclerosis imaging to refine cardiovascular risk assessment in diabetic patients: Computed tomography and positron emission tomography applications.糖尿病患者心血管风险评估的动脉粥样硬化影像学：计算机断层扫描和正电子发射断层扫描的应用。
Atherosclerosis. 2018 Apr;271:77-83. doi: 10.1016/j.atherosclerosis.2018.02.021. Epub 2018 Feb 15.
9
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum.2 型糖尿病的心血管结局试验：我们从何处去？编辑专家论坛的反思。
Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.
10
Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽与2型糖尿病患者的心血管结局
N Engl J Med. 2017 Dec 21;377(25):2502. doi: 10.1056/NEJMc1714163.
Zotero 插件